Evaluation of new anti-infective drugs for the treatment of acute hematogenous osteomyelitis in children

J. D. Nelson, C. Norden, J. T. Mader, G. B. Calandra

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Most children with acute hematogenous osteomyelitis have no preceding illness. Their early symptoms are pain and fever. A bacterial etiology is established in ˜75% of cases by needle aspiration of the affected site or blood culture. Clinical trials should be limited to cases of bacterial origin. The antimicrobial agents studied should be active against Staphylococcus aureus and streptococci. If children < 5 years of age are included, the drug should also be activc against β-Iactamase-negative and -positive strains of Haemophilus influenzae. Randomized, prospective, double-blind comparative studies are preferable to open, evaluator-blinded trials. Clinical outcome is appraised by physical signs and symptoms. A successful microbiological outcome consists of presumptive eradication. The final assessment should be made 1 year after completion of therapy.

Original languageEnglish (US)
Pages (from-to)S162-S166
JournalClinical Infectious Diseases
Volume15
DOIs
StatePublished - Nov 1992

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Evaluation of new anti-infective drugs for the treatment of acute hematogenous osteomyelitis in children'. Together they form a unique fingerprint.

  • Cite this